Compound ID | 605
Caprazamycin C
Class: MraY inhibitor (liponucleoside)
| Details of activity: | Interferes with cell-wall synthesis by inhibiting transfer of the peptidoglycan precursor moiety (MurNAc-pentapeptide) to the membrane lipid carrier, undecaprenyl phosphate. Activity against Mycobacterium tuberculosis |
| Institute where first reported: | Meiji Seika Kaisha, Japan |
| Year first mentioned: | 2002 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| Reason Dropped: | IV only; modest anti-tubercular activity, low intracellular activity. Not great in vivo activity. Many analogues made. Permeability and efflux problems (2). |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.